figshare
Browse
2023-Scientific report_Drp1 inhibitor.pdf (4.34 MB)

A novel small molecule inhibitor of human Drp1

Download (4.34 MB)
journal contribution
posted on 2023-08-25, 05:42 authored by Ayeshah A Rosdah, Belinda M Abbott, Christopher G Langendorf, Yali Deng, Jia Q Truong, Helen MM Waddell, Naomi XY Ling, William J Smiles, Lea MD Delbridge, Guei-Sheung LiuGuei-Sheung Liu, Jonathan S Oakhill, Shiang Y Lim, Jessica K Holien
Mitochondrial dynamin-related protein 1 (Drp1) is a large GTPase regulator of mitochondrial dynamics and is known to play an important role in numerous pathophysiological processes. Despite being the most widely used Drp1 inhibitor, the specificity of Mdivi-1 towards human Drp1 has not been definitively proven and there have been numerous issues reported with its use including off-target effects. In our hands Mdivi-1 showed varying binding affinities toward human Drp1, potentially impacted by compound aggregation. Herein, we sought to identify a novel small molecule inhibitor of Drp1. From an initial virtual screening, we identified DRP1i27 as a compound which directly bound to the human isoform 3 of Drp1 via surface plasmon resonance and microscale thermophoresis. Importantly, DRP1i27 was found to have a dose-dependent increase in the cellular networks of fused mitochondria but had no effect in Drp1 knock-out cells. Further analogues of this compound were identified and screened, though none displayed greater affinity to human Drp1 isoform 3 than DRP1i27. To date, this is the first small molecule inhibitor shown to directly bind to human Drp1.

History

Sub-type

  • Article

Publication title

Scientific Reports

Medium

Electronic

Volume

12

Issue

1

Article number

21531

Pagination

13

eISSN

2045-2322

ISSN

2045-2322

Department/School

Menzies Institute for Medical Research, UTAS Centre for Rural Health

Publisher

NATURE PORTFOLIO

Publication status

  • Published

Place of publication

England

Event Venue

St Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.

Rights statement

Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The